You are here » Home » Companies » Company Overview » Claris Lifesciences Ltd

Claris Lifesciences Ltd.

BSE: 533288 Sector: Health care
NSE: N.A. ISIN Code: INE562G01018
BSE LIVE 15:48 | 22 Nov 346.35 -3.70
(-1.06%)
OPEN

347.15

HIGH

349.95

LOW

345.00

NSE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 347.15
PREVIOUS CLOSE 350.05
VOLUME 88564
52-Week high 430.10
52-Week low 233.30
P/E 1.11
Mkt Cap.(Rs cr) 1,890
Buy Price 0.00
Buy Qty 0.00
Sell Price 345.45
Sell Qty 190.00
OPEN 347.15
CLOSE 350.05
VOLUME 88564
52-Week high 430.10
52-Week low 233.30
P/E 1.11
Mkt Cap.(Rs cr) 1,890
Buy Price 0.00
Buy Qty 0.00
Sell Price 345.45
Sell Qty 190.00

Claris Lifesciences Ltd. (CLARISLIFESCIEN) - Chairman Speech

Company chairman speech

Dear Stakeholders

I am happy to share with you the key business updates and performance of our companyfor the financial year 2016-17 through this Annual Report.

Our continued injectables focus with strategic intent to mark presence in the regulatedmarkets especially the USA has significantly made an impact on the performance andgrowth. During the year over 63 % of the Specialty Injectables Business revenue has beengenerated from the USA. Our portfolio has 15 developed and 16 approved ANDAs in the USAwhile 10 are under development and 24 are in the approval process. To supplement theincreasing demands we have undertaken efforts to strengthen our manufacturingcapabilities by capacity expansion and enhancement in manufacturing through automation.Together the introduction of newer machines and upgradation of select processes in theSCADA system will help us increase productivity and at the same time ensure datareliability to meet regulatory requirements.

The robust pipeline of products cutting-edge manufacturing facilities experiencedmarketing team and a sound governance structure have helped us emerge as a promisingintegrated quality-driven injectables company. Leveraging on our strengths we havesigned a definitive agreement with Baxter a US-based global medical products company. Thecombined organisation will benefit from our world-class integrated business model andBaxter's expertise to advance the business as a strategic platform. I strongly believethat this agreement with Baxter will ensure a promising future for our team memberspartners and stakeholders. Our immediate emphasis is to meet the requirements of thisagreement and eye for its successful closure by the year 2017 for businesses to utilisethe full value of this synergy.

Along with our business obligations we have continued to connect with society at largethrough a variety of corporate social responsibility initiatives in the areas of promotingsports healthcare education and culture among others.

Our HR philosophy and approach are aligned with our business objectives. We have beenrecognised as one of'India's Best Companies to Work For' for the 7th year in a row in astudy by The Economic Times and Great Place to Work Institute India. Also we have beenendowed 'The Great Manager Award 2016'and have been mentioned in the Top 20 list of'Companies with Great Managers' by People Business and The Times of India. Such honoursreceived during the year are a testament of our belief that'people are everything' andthat drives effective leadership and creates a thriving work place culture.

We are committed to deliver on stakeholder expectations with increased profitabilityand credibility. As we move towards the next level of growth and sustainability I thankyou for encouraging us at every stage and seek your continued support in our endeavours.

Arjun Handa